Article
Analysis of baseline parameters in the HALT polycystic kidney disease trials.
Kidney international - 1 Mar 2012
Torres Vicente E, Chapman Arlene B, Perrone Ronald D, Bae K Ty, Abebe Kaleab Z, Bost James E, Miskulin Dana C, Steinman Theodore I, Braun William E, Winklhofer Franz T, Hogan Marie C, Oskoui Frederic R, Kelleher Cass, Masoumi Amirali, Glockner James, Halin Neil J, Martin Diego R, Remer Erick, Patel Nayana, Pedrosa Ivan, Wetzel Louis H, Thompson Paul A, Miller J Philip, Meyers Catherine M, Schrier Robert W
Abstract excerpt
HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.